Advertisement

Topics

NeuroVive's KL1333 Receives FDA Orphan Drug Designation for Treatment of Mitochondrial Diseases

03:43 EDT 18 Apr 2018 | FinanzNachrichten

LUND, Sweden, April 18 2018 /PRNewswire/ --NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP) (OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has been granted Orphan Dr...

Original Article: NeuroVive's KL1333 Receives FDA Orphan Drug Designation for Treatment of Mitochondrial Diseases

NEXT ARTICLE

More From BioPortfolio on "NeuroVive's KL1333 Receives FDA Orphan Drug Designation for Treatment of Mitochondrial Diseases"

Advertisement
Quick Search
Advertisement
Advertisement